[Randomized, blind, parallel-controlled and multiple-centre clinical trial on the effectiveness and safety of leuprolide acetate in the treatment of endometriosis].
OBJECTIVE
To evaluate the effectiveness and safety of leuprolide acetate in the treatment of endometriosis.


METHODS
From Nov. 2007 to Oct. 2012, the patients who confirmed to be endometriosis were randomly divided into test group of 113 cases and control group of 116 cases. The test drug was the sustained-release agent of leuprolide acetate. The control drug was Enantone. The drugs were used for 3 times in total. After treatment, the ovarian mass volumes measured with type-B ultrasound, the scores of the patient's subjective symptoms during non-menstrual and menstruation days, the pelvic signs during non-menstrual days, the changes of hormones [estradiol (E2), FSH, LH], and adverse events were observed.


RESULTS
After the treatment, the rate of changes of ovarian mass volume (among them, at 12 weeks after the first injection, the median was -55.83% in the test group, -68.22% in the control group, P = 0.336), the distinct improvement rate of symptom scores and pelvic signs during non-menstrual days [among them, at 12 weeks after the first injection, the rate of lower abdomen pain was 47.5% (48/101) in the test group, 44.0% (44/100) in the control group, P = 0.881], the hormone (E2, FSH, LH) levels [among them, at 12 weeks after the first injection, the serum level of E2, was (33±38) pmol/L in the test group, (38±40) pmol/L in the control group, P = 0.414; the serum level of FSH, was (5.1±2.8) U/L in the test group, (5.3±2.3) U/L in the control group, P = 0.666; the serum level of LH, was (0.6±0.8) U/L in the test group, (0.6±0.9) U/L in the control group, P = 0.907], had no statistically significant difference between the two groups (all P > 0.05). The distinct improvement rate and improvement rate of symptom (lower abdomen pain, low back pain) scores during menstruation days at 12 weeks after the first injection, the rates of lower abdomen pain were 73.9% (34/46), 15.2% (7/46) respectively in the test group, 72.3% (34/47), 2.1% (1/47) respectively in the control group, had statistically significant difference between the two groups (P = 0.026). There was no serious adverse event occurred in both two groups. The incidence rate of adverse event was 33.6% (38/113) in test group, 23.2% (27/116) in control group, there was no significant difference between the two groups (P = 0.082).


CONCLUSIONS
Leuprolide acetate is effective and safe in the treatment of endometriosis.
Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing 100029, China.
Meilu
M
Bian
Shuhui
S
Huang
Wenhong
W
Deng
Jinghui
J
Song
Zhiqing
Z
Liang
Yan
Y
Zhang
Ying
Y
Jin
Hong
H
Zhu
Mingzhe
M
Liu
Quyuan
Q
Wang
Yu
Y
Yang
Email: chqyun@163.com.
Qingyun
Q
Chen
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D004715:Endometriosis / Q000188:drug therapy*; D004958:Estradiol; D005260:Female; D006728:Hormones; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D003692:Delayed-Action Preparations; D006728:Hormones; D004958:Estradiol; D016729:Leuprolide